secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2022-06-30T23:59:59+00:00
Accession:  0001558370-22-010491
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix appoints Shmuel Ben Zvi to board; stockholders approve share increase to 144M
--------------------------------------------------------------------------------

- Dr. Shmuel Ben Zvi appointed as independent director, joining Audit and Compensation Committees.
- Stockholders approved amendment to increase authorized common shares from 120M to 144M.
- Stockholders approved 2006 Stock Plan amendment raising available shares from ~5.7M to ~8.5M.
- Advisory vote on executive compensation passed with ~80% of votes cast in favor.
- All six director nominees elected; Kesselman & Kesselman ratified as auditor for FY2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837022010491/0001558370-22-010491-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837022010491/plx-20220629x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-010491

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer